Early Intrapleural TPA Instillation Versus Late — ELEVATE  

Tissue Plasminogen Activator Clinical Trial

Official title: Early Intrapleural TPA Instillation Versus Late

Status Withdrawn

Clinical Trial Summary

Chest tubes are used for air or fluid removal from the pleural space. When a chest tube is placed, it can be hard for the fluid to drain.Tissue plasminogen activator (tPA) and DNase are given through the chest tube to help with draining the fluid. We are doing this research to see if early addition of tPA-DNase immediately after chest tube placement will help with better fluid draining.

Clinical Trial Description

The purpose of this study is to determine the timing and efficacy of early administration and late administration of t-PA/DNase via thoracostomy (n=60). Patients will be identified from the Intensive Care Unit, Coronary Care Unit, and wards/stepdown units. Prior to chest tube placement, patients will be randomized to one of the two treatment arms (early use of t-PA-DNase verus late use of t-PA-DNase). Route of administration will be via their thoracostomy tube over a period of three days twice daily. ;

Related Conditions & MeSH terms

• Tissue Plasminogen Activator

• NCT number: NCT03167281
• Study type: Interventional
• Source: Prisma Health-Midlands
• Status: Withdrawn
• Phase: Phase 4
• Start date: February 17, 2017
• Completion date: March 10, 2021